Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with FLT3-ITD Mutation].

Zhongguo shi yan xue ye xue za zhi - 1 Oct 2023

Weng Guang-Yang, You Wei-Wen, Liu Huan-Xun, Cai Yun, DU Xin

Abstract excerpt

OBJECTIVE: To explore the efficacy of venetoclax (VEN) plus azacitidine (AZA) in patients with FLT3-ITD mutated relapsed/refractory acute myeloid leukemia (FLT3-ITDmut R/R AML) and analyze the molecular genetic characteristics of the patients. METHODS: Clinical baseline characteristics and follow-up data of 16 R/R AML patients treatd with VEN plus AZA in the hematology department of Shenzhen Second People's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nucleophosmin

Share to Prognosis

Source

Identifiers

PMID: 37846681
DOI: 10.19746/j.cnki.issn.1009-2137.2023.05.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with FLT3-ITD Mutation].PMID 37846681Read ↗

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center studySemantic proximity Read ↗

Efficacy of venetoclax and azacitidine based therapy in favorable-risk unfit acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity Read ↗

Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.Semantic proximity Read ↗

Venetoclax combined with hypomethylating agents and the CAG regimen (DCAG) in relapsed/refractory AML: A single- center clinical trialSemantic proximity Read ↗

A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxSemantic proximity Read ↗

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.Semantic proximity Read ↗

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AMLSemantic proximity Read ↗

Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with <i>IDH 1/2</i> MutationsSemantic proximity Read ↗

Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real- world single-center experienceSemantic proximity Read ↗

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.